Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry
2007; 68 (suppl 14): 14–9.
Weiden, PJ, Kozma, C, Grogg, A, Locklear, J.
Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv
2004; 55: 886–91.
Subotnik, KL, Nuechterlein, KH, Ventura, J, Gitlin, MJ, Marder, S, Mintz, J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry
2011; 168: 286–92.
Heres, S, Lambert, M, Vauth, R.
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry
2014; 29 (suppl 2): 1409–13.
Marcus, SC, Zummo, J, Pettit, AR, Stoddard, J, Doshi, JA.
Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm
2015; 21: 754–68.
Kirson, NY, Weiden, PJ, Yermakov, S, Huang, W, Samuelson, T, Offord, SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry
2013; 74: 568–75.
The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry
1984; 45: 22–7.
Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol
1995; 9 (suppl 5): 17–20.
Agid, O, Foussias, G, Remington, G.
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother
2010; 11: 2301–17.
Waddell, L, Taylor, M.
Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry
Patel, MX, De Zoysa, N, Bernadt, M, David, A.
Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol
2009; 23: 789–96.
Weiden, PJ, Roma, RS, Velligan, Dl, Alphs, L, DiChiara, M, Davidson, B.
The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry
2015; 76: 684–90.
Beitinger, R, Kissling, W, Hamann, J.
Trends and perspectives of shared decision-making in schizophrenia and related disorders. Curr Opin Psychiatry
2014; 27: 222–9.
Potkin, S, Bera, R, Zubek, D, Lau, G.
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry
2013; 13: 261.
Das, AK, Malik, A, Haddad, PM.
A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol
2014; 4: 179–85.
Patel, MX, Haddad, PM, Chaudhry, IB, McLoughlin, S, Husain, N, David, AS.
Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol
2010; 24: 1473–82.
James, BO, Omoaregba, JO, Okonoda, KM, Otefe, EU, Patel, MX.
The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria. Ther Adv Psychopharmacol
2012; 2: 169–77.
Subotnik, KL, Casaus, LR, Ventura, J, Luo, JS, Helleman, GS, Gretchen-Doorly, D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry
2015; 72: 822–9.